Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18400722 | 0.87 | CYP1A2 (0.54) | CYP1A2HRH3HRH1ALDH1A1LMNA | |
| SCHEMBL23869693 | 0.86 | CYP1A2 (0.53) | CYP1A2HRH3HRH1ALDH1A1LMNA | |
| SCHEMBL19465295 | 0.84 | CYP1A2 (0.46) | CYP1A2HRH3HRH1ALDH1A1LMNA | |
| SCHEMBL22420936 | 0.82 | CYP1A2 (0.56) | CYP1A2HRH3HRH1ALDH1A1LMNA | |
| SCHEMBL23897418 | 0.82 | CYP1A2 (0.53) | CYP1A2HRH3HRH1ALDH1A1LMNA | |
| SCHEMBL30195799 | 0.81 | CYP1A2 (0.58) | CYP1A2HRH3HRH1ALDH1A1LMNA | |
| SCHEMBL116939 | 0.81 | CYP1A2 (0.58) | CYP1A2HRH3HRH1ALDH1A1LMNA | |
| SCHEMBL21025180 | 0.79 | CYP1A2 (0.53) | CYP1A2ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL22421066 | 0.79 | CYP1A2 (0.53) | CYP1A2HRH3HRH1ALDH1A1LMNA | |
| SCHEMBL29583126 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339172-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20200385395-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-9804168-B2 | Biomarker discovery in complex biological fluid using bead or particle based libraries and diagnostic kits and therapeutics | OPKO PHARMACEUTICALS, LLC (US) | 2017-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200385395-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ADRB3, ADRB1, ADRB2 | CYP1A2 672/4885HRH3 599/4885HRH1 429/4885 |
| US-11339172-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ADRB3, ADRB1, ADRB2 | CYP1A2 633/4885HRH3 625/4885HRH1 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.